Immuno-Oncology | Specialty

Dr. Sharpless on Managing Toxicities With Nivolumab and Ipilimumab in Melanoma

May 5th 2016

Norman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses how oncologists can best manage toxicities associated with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

Expert Discusses Latest Findings With Nivolumab/Ipilimumab Combo in Melanoma

April 29th 2016

Patrick Ott, MD, PhD, discusses toxicity management and patient selection considerations required with the combination of nivolumab (Opdivo)/ipilimumab (Yervoy), and its role in BRAF-mutant melanoma.

Radium-223 May Enhance Immune Response With Sipuleucel-T in mCRPC

April 26th 2016

Jong Chul Park, MD, discusses the potential synergy of radium-223 and sipuleucel-T, which is being investigated in a clinical trial as a potential treatment for patients with metastatic castration-resistant prostate cancer.

FDA Grants Nivolumab Breakthrough Designation for Head and Neck Cancer

April 25th 2016

The FDA has granted a breakthrough therapy designation to nivolumab as a single-agent treatment for patients with recurrent or metastatic squamous cell carcinoma of the head and neck following a platinum-based therapy.

Dr. Kelly on the JAVELIN Solid Tumor Trial

April 22nd 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of the phase Ib JAVELIN Solid Tumor Trial.

Expert Hopes Immunotherapy Combos Will Deliver Durable Remissions in RCC

April 21st 2016

Robert Figlin, MD, discusses some emerging agents and ongoing trials that could transform the treatment landscape of renal cell carcinoma.

Twitter Becomes Forum for Opdivo Coverage Dispute

April 20th 2016

Social media has become an outlet for expressing frustration with the struggle to get insurance approvals for oncology tests and treatments.

Dr. Ferris on CheckMate-141 Trial in Head and Neck Cancer

April 20th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).

Dr. Khleif on Next Steps to Take With Immunotherapy

April 19th 2016

Samir N. Khleif, MD, director, GRU Cancer Center, discusses next steps researchers and physicians need to take with immunotherapy in the field of oncology.

Nivolumab Doubles 1-Year OS Rates in Head and Neck Cancer

April 19th 2016

Treatment with single-agent nivolumab reduced the risk of death by 30% and double 1-year overall survival rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

PD-L1 Expression Assays Show Similar Performance for NSCLC

April 19th 2016

Three currently available assays for PD-L1 expression exhibited a high degree of correlation in a comparative study involving archived lung cancer tissue.

Pembrolizumab Granted Breakthrough Designation for Hodgkin Lymphoma

April 18th 2016

The FDA has granted a breakthrough therapy designation to pembrolizumab as a treatment for patients with relapsed or refractory classical Hodgkin lymphoma.

Yong-Chen William Lu on Adoptive T-Cell Therapy in Solid Tumors

April 18th 2016

Yong-Chen William Lu, PhD, a fellow in the Surgery Branch of the National Cancer Institute, discusses a CD4 T-cell immunotherapy targeting MAGE-A3 that is showing early clinical responses in patients with metastatic cancer.

Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma

April 17th 2016

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, discusses the results of the longest follow-up survival study of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

Nivolumab Shows Impressive Long-Term OS in Melanoma

April 17th 2016

Single-agent nivolumab demonstrated a robust 5-year overall survival rate of 34% for heavily pretreated patients with metastatic melanoma who had not received prior ipilimumab.

Dr. Raffaele Califano on Immunotherapy in Small-Cell Lung Cancer

April 16th 2016

Raffaele Califano, MD, consultant in medical oncology at the Christie NHS Foundation Trust and University Hospital of South Manchester, discuses the potential for immunotherapy in small-cell lung cancer (SCLC).

Higher Cytokine Levels Improve Nivolumab Efficacy in Squamous NSCLC

April 16th 2016

Efficacy and safety remained strong 2 years following treatment with nivolumab for patients with advanced, refractory, squamous non-small–cell lung cancer, with an indication that cytokine levels could predict long-term outcomes.

Dr. John Haanen on the Role of PD-L1 in Lung Cancer

April 14th 2016

John Haanen, MD PhD, epartment of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, discussed the role of PD-L1 as a biomarker in lung cancer.

FDA Grants Nivolumab Priority Review in Hodgkin Lymphoma

April 14th 2016

The FDA has granted nivolumab (Opdivo) a priority review for use in previously treated patients with classical Hodgkin lymphoma.

FDA Grants Priority Review to Pembrolizumab for Head and Neck Cancer

April 13th 2016

The FDA has granted a priority review designation to pembrolizumab (Keytruda) as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.

NEXT PAGE
PREVIOUS PAGE